Skip to main content

Evolus, Inc.

corporate_fare Company Profile

Evolus, Inc.

EOLS·NASDAQ·Life Sciences·CIK 0001570562

We are a global performance beauty company focused on the cash-pay aesthetic market, where consumers pay directly for medical products. Our customers are licensed aesthetic practitioners. We offer products in two major categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Our commercially available neurotoxin product is Jeuveau®, a proprietary 900 kilodalton (kDa) purified botulinum toxin type A formulation. It is indicated for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Jeuveau® is an alternative to BOTOX (onabotulinumtoxinA) and is supported by our TRANSPARENCY global clinical program, which involved over 2,100 patients and included a head-to-head Phase III study comparing Jeuveau® and BOTOX. Jeuveau® is currently available in the United States, Canada, certain European markets, and Australia, with plans for expansion into additional European markets. Our HA gel product line is Evolysse™, which uses first-generation cold technology. This collection of injectable HA gels includes products for various applications such as mid-face, nasolabial folds, lips, and eyes.

Evolus, Inc. (NASDAQ:EOLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for EOLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for EOLS spans 10-Q, 8-K, S-3, 10-K.

Recent high-impact activity:

  • Evolus 10-Q: $41.7M Cash, $120M Undrawn Debt, Accelerated Jeuveau Inventory Build
  • Evolus Posts 13% Revenue Growth, Fourth Straight Positive Adjusted EBITDA, Reaffirms 2026 Outlook
  • FDA Flags Jeuveau Instagram Post as Misleading, Evolus Shares Drop
  • Evolus Delivers 21% Revenue Jump to $83M in Q2, Sharply Narrows Losses
  • Evolus Raises 2026 Outlook After Q2 Revenue Jumps 21%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$297.18M
Net Income
-$51.64M
Diluted EPS
-$0.80
Op. Cash Flow
-$42.27M
Free Cash Flow
-$45.71M
Gross Profit
$197.11M
Operating Income
-$32.66M
Cash & Equivalents
$53.83M
Total Debt
$146.1M
Debt / Equity
-6.32×
Net Margin
-17.4%
Shares Outstanding
65.01M sh
Source: 10-K · filed 2026-03-03 · accession 0001628280-26-014001

Short Interest & Short Volume

9.38 days to cover

FINRA reported short interest of 6,023,009 shares in EOLS as of the October 30, 2026 settlement, a 6.0% decrease from the prior period — about 9.4 days to cover at its recent average daily volume. On November 20, 2026, 55.2% of EOLS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,023,009 shares as of October 30, 2026
Change vs prior period▼ 6.0%
Days to cover9.38 at avg daily volume of 642,143
Daily short volume (FINRA facilities)55.2% of 326,457 shares on November 20, 2026
5-day average short volume58.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for EOLS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.

1 shelf registration

Universal Shelf Registration Filed · Renewal of Expiring Program

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$6.5 -0.31% today
52-week range · as of 2026-11-04 $3.86 – $9.31
Market cap
$431.55M
Volume
813.6K (0.8× avg)
3-mo avg 987.2K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EOLS - Latest Insights

EOLS
Nov 04, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.39
Real-time Price: $6.50 info
Change: -$0.890 (-12%) info
Market Cap: $431.548M info
EOLS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $7.47
Real-time Price: $6.50 info
Change: -$0.970 (-13%) info
Market Cap: $431.548M info
EOLS
Oct 02, 2026, 10:45 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $7.19
Real-time Price: $6.50 info
Change: -$0.685 (-10%) info
Market Cap: $431.548M info
EOLS
Aug 05, 2026, 4:56 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.53
Real-time Price: $6.50 info
Change: -$0.030 (-0.46%) info
Market Cap: $431.548M info
EOLS
Aug 05, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $6.50 info
Change: -$0.170 (-3%) info
Market Cap: $431.548M info
EOLS
Aug 04, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $6.50 info
Change: +$0.450 (+7%) info
Market Cap: $431.548M info
EOLS
Aug 04, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $6.50 info
Change: +$0.450 (+7%) info
Market Cap: $431.548M info
EOLS
Jul 08, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.50 info
Change: -$0.350 (-5%) info
Market Cap: $431.548M info
EOLS
Jun 05, 2026, 4:46 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $6.67
Real-time Price: $6.50 info
Change: -$0.170 (-3%) info
Market Cap: $431.548M info
EOLS
May 04, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $6.50 info
Change: +$0.8874 (+16%) info
Market Cap: $431.548M info
EOLS
May 04, 2026, 4:24 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.50 info
Change: +$0.720 (+12%) info
Market Cap: $431.548M info
EOLS
May 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.65
Real-time Price: $6.50 info
Change: +$0.850 (+15%) info
Market Cap: $431.548M info
EOLS
Mar 03, 2026, 5:01 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.91
Real-time Price: $6.50 info
Change: +$1.59 (+32%) info
Market Cap: $431.548M info
EOLS
Mar 03, 2026, 4:21 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $6.50 info
Change: +$1.75 (+37%) info
Market Cap: $431.548M info
EOLS
Mar 03, 2026, 4:05 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $6.50 info
Change: +$2.05 (+46%) info
Market Cap: $431.548M info
EOLS
Jan 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.59
Real-time Price: $6.50 info
Change: +$0.910 (+16%) info
Market Cap: $431.548M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets